| | 
Part, Chapter, Paragraph
1 -, 1 | process (from 15 November 2005 to November 2008), begun
2 I, 2. 2 | import and export) was 19% in 2005 (the same as in the USA
3 I, 2. 4 | economically developed (Eurostat, 2005). Even broader gaps can
4 I, 2. 4 | can be observed (APPLICA, 2005; Table 2.2).~ ~Table 2.2.
5 I, 2. 4 | Report prepared by APPLICA, 2005; Semenza and Giesecke, American
6 I, 2. 4 | presidency of the EU in October 2005, and other documents clearly
7 I, 2. 5 | in 1995 to 71 per cent in 2005 in developed countries.
8 I, 2. 5 | satisfaction (EUROFOUND, 2005). Key factors for workers’
9 I, 2. 5 | increase by almost 9% from 2005 to 2010, but the number
10 I, 2. 5 | Finnish Heart Association, 2005). These issues have a gender
11 I, 2. 5 | of the workforce (Ivanov, 2005). People living under long-term
12 I, 2. 7 | Marrone, 2007; Arcury et al, 2005).~ ~Human settlements have
13 I, 2. 10. 3 | In particular, the Europe 2005 Action Plan targeted a dynamic
14 I, 2. 10. 3 | regulatory reforms. The e-Europe 2005 Action Plan has now been
15 I, 2. 10. 3 | services.~ ~E-Contentplus (2005-2008) supports the development
16 I, 2. 10. 4(10)| la hospilitizacion (ENEAS 2005). Informe. Febrero 2006.
17 I, 2. 10. 4 | Customs, a 384% growth versus 2005(14). It is likely that counterfeiting
18 I, 2. 10. 4 | increase of more than 90% from 200515.~ ~The introduction of
19 I, 2. 10. 4(18)| De Scioli D. (2005). Differatiating the Hospital
20 I, 2. 11 | 11. References~ ~APPLICA (2005): Network on Social Inclusion
21 I, 2. 11 | Social Affairs). December 2005 [on-line publication available
22 I, 2. 11 | Spencer, J., Perin, J. (2005): The effects of geography
23 I, 2. 11 | conditions (EUROFOUND) (2005): High performance workplace
24 I, 2. 11 | Available at: htt ~ ~EUROSTAT (2005):. Regions: statistical
25 I, 2. 11 | Regions: statistical yearbook 2005. Data 1999-2003. [on-line
26 I, 2. 11 | Finnish Heart Association (2005): Action Plan for Promoting
27 I, 2. 11 | Heart Health for the Years 2005-2011. Helsinki, Finnish
28 I, 2. 11 | Oberdörster G. et al., (2005): Nanotoxicology: An emerging
29 I, 2. 11 | Tsolova S, Mortensen J (2005): The impact of health on
30 I, 3. 1 | States in 1960, 1980 and 2005 and the forecast for 2050~ ~
31 I, 3. 1 | everywhere in the EU. In 2005 Ireland (1.88) and France (
32 I, 3. 1 | fertility rates below 1.5 in 2005.~ ~The overall fertility
33 I, 3. 1 | cohort 1955, who turned 50 in 2005 (i.e. they are currently
34 I, 3. 2 | per 1,000 population), 2005~ ~The recent enlargement
35 I, 3. 3 | 1963 (43 years of age in 2005). People born in later years
36 I, 3. 3 | 21.6 in 1980 to 25.5 in 2005. The country specific trends
37 I, 3. 3 | on average from 25.9 in 2005 to 53.2 in 2050. This means
38 I, 3. 3 | States. Compared to the 2005 values, all ratios will
39 I, 3. 3 | annual growth rates from 2005 to 2049. Their old-age-dependency
40 I, 3. 3 | various age groups in 1975, 2005, 2010 and 2025, the following
41 II, 4. 1 | some drops over the 1980-2005 period. Here males had in
42 II, 4. 1 | Indicator on health and in its 2005 annual report to the Spring
43 II, 4. 1 | the European Communities, 2005).~ ~However, the significant
44 II, 4. 1 | expectancy estimates for 2005 were computed using the
45 II, 4. 1 | estimates for the EU25 in 2005 were computed with an algorithm
46 II, 4. 1 | Living Conditions (SILC 2005).~ ~SILC contains the Minimum
47 II, 4. 1 | activity limitation), are for 2005 and were collected or estimated
48 II, 4. 1 | for all Member States in 2005.~ ~Trends in DFLE for the
49 II, 4. 1 | LE estimates from 1995 to 2005 for the 27 current MS were
50 II, 4. 1 | for France and Italy in 2005 (see above).~ ~All health
51 II, 4. 1 | 1.1 shows estimates for 2005 at European level (EU25)
52 II, 4. 1 | European Union (EU25), in 2005, per gender.~ ~The number
53 II, 4. 1 | Life Years (HLY) lived in 2005 by the inhabitants of the
54 II, 4. 1 | Table 4.1.1). Although in 2005 the EU life expectancy at
55 II, 4. 1 | Union (EU27), from 1995 to 2005, per gender~ ~Over the 10
56 II, 4. 1 | the 10 year period 1995-2005, life expectancy at birth
57 II, 4. 1 | European Union (EU25), in 2005, per gender~ ~Table 4.1.
58 II, 4. 1 | between the Member States in 2005. At MS level, values of
59 II, 4. 1 | life expectancy at birth in 2005 range from 65.3 years to
60 II, 4. 1 | between the Member States in 2005 at 50 and 65. Indeed at
61 II, 4. 1 | of the European Union in 2005 (EU25), for men and women,
62 II, 4. 1 | with Severe Limitations, in 2005, Men~ ~Figure 4.1.2. Life
63 II, 4. 1 | with Severe Limitations, in 2005, Women.~ ~ ~The calculation
64 II, 4. 1 | estimated by the HLY in 2005. Around 20% (19% for men
65 II, 4. 1 | of the older workers. In 2005 the gaps between the MS
66 II, 4. 1 | to the next (Robine et al 2005).~ ~One of the main criteria
67 II, 4. 1 | and Japan in 1995 and in 2005 and by gender. The US data
68 II, 4. 1 | and in Japan in 1995 and 2005, per gender~ ~Table 4.1.
69 II, 4. 1 | 5 shows firstly that by 2005 LE at birth is almost identical
70 II, 4. 1 | the 10-year period 1995-2005 and the second largest (
71 II, 4. 2 | average change in the 2000-2005 period, the pattern is similar:
72 II, 4. 2 | Standardized death rates in EU27 in 2005~ ~Inequalities in life expectancy.
73 II, 4. 3 | the European Communities (2005): 2005 Commission Communication
74 II, 4. 3 | European Communities (2005): 2005 Commission Communication
75 II, 4. 3 | the Lisbon Strategy. COM(2005): 24.~ ~Jagger, C. and EHEMU
76 II, 4. 3 | Jagger, C. and EHEMU Team (2005): Healthy life expectancy
77 II, 4. 3 | Deaths: Preliminary Data for 2005, U.S. National Center for
78 II, 4. 3 | Abridged Life Tables for Japan 2005. Tokyo, Statistics and Information
79 II, 4. 3 | M., S. Le Roy, et al. (2005): Changes in life expectancy
80 II, 5. 1. 1 | compare to men (Parkin et al, 2005). Although male lung cancer
81 II, 5. 2. 1 | al, 2008; Petersen et al, 2005).~Even though clinical onset
82 II, 5. 2. 4 | in 1995-96, 1999-2000 and 2005-6 in different European
83 II, 5. 2. 5 | mortality decline (Unal et al, 2005).~The falling rates have
84 II, 5. 2. 5 | of life (Daviglus et al, 2005). It is commonly believed
85 II, 5. 2. 5 | Luxembourg Declaration – 29 June 2005), adopted under the Luxembourg
86 II, 5. 2. 6 | mortality (Baigent C et al, 2005). The available information,
87 II, 5. 2. 6 | Trialists' (CTT) Collaborators (2005). Efficacy and safety of
88 II, 5. 2. 6 | Maheshwari N, Schrott H (2005). Pleiotropic effects of
89 II, 5. 2. 7 | Wang R, Lubitz J et al (2005): Cardiovascular risk profile
90 II, 5. 2. 7 | Luengo-Fernandez R and Gray A (2005): European cardiovascular
91 II, 5. 2. 7 | JA, Fidan D, Capewell S (2005): Life-Years Gained from
92 II, 5. 3. 2 | Commission and started in 2005, involves Denmark, France,
93 II, 5. 3. 2 | MOSES-II, by the end of 2005, collected data from 34
94 II, 5. 3. 4 | compared to men (Parkin et al, 2005). Although male lung cancer
95 II, 5. 3. 5 | invasive cancers (Parkin et al, 2005). The screening effect on
96 II, 5. 3. 5 | entire Europe (Parkin et al, 2005). The risk of developing
97 II, 5. 3. 6 | In EUROCARE, Gatta et al (2005) analyzed survival in 129,
98 II, 5. 3. 7 | ESTONIA~Yes~IRELAND~Yes (2005)~GREECE~No~SPAIN~Yes (regional)~
99 II, 5. 3. 9 | EUROCARE Working Group (2005): Childhood Cancer Survival
100 II, 5. 3. 9 | Bray F, Ferlay J, Pisani P (2005): Global cancer statistics,
101 II, 5. 4. 8 | Orsini M, Massi Benedetti M (2005), Diabetes registers and
102 II, 5. 4. 8 | idf.org/EU_diabetes_report_2005]~(report online, accessed
103 II, 5. 5.Int(10)| McCollam A, Woodhouse A (2005): Equal minds. Scottish
104 II, 5. 5.Int | Conclusions adopted in June 2005 reinforced this message
105 II, 5. 5.Int | the implementation.~ ~In 2005, the European Commission
106 II, 5. 5. 1 | misuse (Sullivan et al, 2005), but is also associated
107 II, 5. 5. 1 | substance misuse (Mann et al., 2005). Major depression is found
108 II, 5. 5. 1 | death rate) in 1995 and 2005 in the EU. Source: Eurostat~ ~
109 II, 5. 5. 1 | depression in Sweden from 1997 to 2005. Eur Psychiatry 22(3):146-
110 II, 5. 5. 1 | Psychiatry 22(3):146-52.~ ~S G (2005). The prevalence and impact
111 II, 5. 5. 2 | carried out by Ferri et al (2005) on behalf of Alzheimer’
112 II, 5. 5. 2 | the statistics were from 2005. Those for the UK and Estonia
113 II, 5. 5. 2 | EURODEM and Ferri et al (2005) studies are as follows.
114 II, 5. 5. 2 | reported by Ferri et al (2005)~ ~Using these prevalence
115 II, 5. 5. 2 | member states from 1960 to 2005 (Alzheimer Europe, 2006a).
116 II, 5. 5. 2 | has increased from 1960 to 2005. This increase is linked
117 II, 5. 5. 2 | the period from 1960 to 2005, the number of people with
118 II, 5. 5. 2 | upward trend.~ ~Ferri et al (2005) made estimates of future
119 II, 5. 5. 2 | with them (Godfrey et al, 2005). It is becoming increasingly
120 II, 5. 5. 2 | inconclusive (Godfrey et al, 2005).~ ~Secondary Prevention~
121 II, 5. 5. 2 | Ferri CL, Prince M et al (2005): Global prevalence of dementia:
122 II, 5. 5. 2 | Boyle G and Brooker D (2005): Summary report for the
123 II, 5. 5. 3 | Adolescence (HELENA started in 2005, ends in 2008) aims at understanding
124 II, 5. 5. 3 | were published from 1980 to 2005 and explain the results
125 II, 5. 5. 3 | policy and intervention (WHO, 2005):~· provide accurate and
126 II, 5. 5. 3 | Related Eating Disorders Inc, 2005).~In the future, the European
127 II, 5. 5. 3 | Related Eating Disorders Inc. (2005): Eating disorders prevention:
128 II, 5. 5. 3 | Health Organization (WHO) (2005): The European Health Report
129 II, 5. 5. 3 | The European Health Report 2005 – Part 3 Child an adolescent
130 II, 5. 5. 3 | systematic review (Saha et al, 2005) of prevalence data evaluated
131 II, 5. 5. 3 | schizophrenia (Wrigley et al, 2005). The quality of psychiatric
132 II, 5. 5. 3 | support (Andlin-Sobocki et al, 2005).~Schizophrenia belongs
133 II, 5. 5. 3 | is derived from the year 2005), data from countries like
134 II, 5. 5. 3 | morbidity risk (Saha et al, 2005). These findings are reported
135 II, 5. 5. 3 | illness onset” (Palmer et al, 2005), a comparison of suicide
136 II, 5. 5. 3 | Disability adjusted life-years~In 2005, neuropsychiatric conditions
137 II, 5. 5. 3 | data of 2002 for the year 2005: In the WHO European Region
138 II, 5. 5. 3 | medication (Holt et al, 2005).~A great deal of co-morbid
139 II, 5. 5. 3 | psychosis. (Klosterkötter et al, 2005; Klosterkötter, 2007).~The
140 II, 5. 5. 3 | al, 2006; Gaebel et al, 2005; AGREE Collaboration, 2003) –
141 II, 5. 5. 3 | distance (Gaebel et al, 2005).~Direct and indirect costs
142 II, 5. 5. 3 | Andlin-Sobocki & Rössler, 2005).~In 2004, the costs for
143 II, 5. 5. 3 | paper (European Commission, 2005) and the WHO Helsinki Declaration (
144 II, 5. 5. 3 | European Ministerial Conference 2005~www. Mental health promotion
145 II, 5. 5. 3 | backgrounds (Gaebel et al, 2005). Another solution, as suggested
146 II, 5. 5. 3 | Interventions and Policy Options” (2005) mentions 7 groups of disorders
147 II, 5. 5. 3 | Wittchen HU, Olesen J (2005): Cost of disorders of the
148 II, 5. 5. 3 | Andlin-Sobocki P, & Rössler W (2005):Cost of psychotic disorders
149 II, 5. 5. 3 | 206.~European Commission (2005): Green Paper. Improving
150 II, 5. 5. 3 | N, Rutz W, McIntyre JS (2005): Schizophrenia practice
151 II, 5. 5. 3 | RI, Bushe C, Citrome L (2005): Diabetes and schizophrenia
152 II, 5. 5. 3 | Diabetes and schizophrenia 2005: are we any closer to understanding
153 II, 5. 5. 3 | Hambrecht M, VON Reventlow H (2005): The European Prediction
154 II, 5. 5. 3 | Pankratz VS, Bostwick JM (2005): The lifetime risk of suicide
155 II, 5. 5. 3 | Saha S, Chant D, McGrath J (2005): A systematic review of
156 II, 5. 5. 3 | in the Nordic Countries 2005 - Mental health in the Nordic
157 II, 5. 5. 3 | Copenhagen, Helsinki 10. Jan. 2005. Available at: htt 1; last
158 II, 5. 5. 3 | Jackson H, Judd F, Komiti A (2005): Role of stigma and attitudes
159 II, 5. 5. 3 | among others (Fombonne, 2005).~ ~It is not possible to
160 II, 5. 5. 3 | autism in the UK.~Since 2005, ASD has been included in
161 II, 5. 5. 3 | Reports, Nov-Dec.~Fombonne E (2005): Epidemiology of autistic
162 II, 5. 5. 3 | Journal of Clinical Psychiatry 2005, 66 (suppl. 10)~Knapp M,
163 II, 5. 5. 3 | conducted (Forsgren et al, 2005). In these studies, the
164 II, 5. 5. 3 | 100,000 (Forsgren et al, 2005; Olafsson et al, 2005).
165 II, 5. 5. 3 | al, 2005; Olafsson et al, 2005). The incidence is higher
166 II, 5. 5. 3 | to 56% (Forsgren et al, 2005). The differences are mostly
167 II, 5. 5. 3 | Iceland (Olafsson et al, 2005), the incidence of single
168 II, 5. 5. 3 | Europe (Forsgren et al, 2005). The overall prevalence
169 II, 5. 5. 3 | 2004 and Forsgren et al., 2005~ ~Country ~Population ~Design~
170 II, 5. 5. 3 | 2001(*)/Gallitto et al, 2005~Italy ~Children ~MR review~? ~
171 II, 5. 5. 3 | perspective (Beghi and Sander, 2005). From a patient’s perspective,
172 II, 5. 5. 3 | rate ratio, RR 1.8)(Vaa, 2005) and the risk of serious
173 II, 5. 5. 3 | across Europe. On April 27 2005, the SEWGED submitted a
174 II, 5. 5. 3 | 63.~Beghi E, Sander JW (2005): Epilepsy and driving.
175 II, 5. 5. 3 | Beghi E, Oun A, Sillanpaa M (2005): The epidemiology of epilepsy
176 II, 5. 5. 3 | Serra S, La Spina P, et al (2005): Prevalence and characteristics
177 II, 5. 5. 3 | P, Gudmundsson G, et al (2005): Incidence of unprovoked
178 II, 5. 5. 3 | Epilepsy Res 60:1-16.~Vaa T (2005): Impairments, diseases,
179 II, 5. 5. 3 | accessed 10 May 2005).~Van den Broek M, Beghi
180 II, 5. 5. 3 | Society (Flachenecker et al, 2005; www ). This project aimed
181 II, 5. 5. 3 | annual cost per patient in 2005, total direct costs (healthcare
182 II, 5. 5. 3 | burden of MS for the year 2005 was €13 billion, i.e., €
183 II, 5. 5. 3 | dominate with €2.5 billion in 2005 (41% of direct costs or
184 II, 5. 5. 3 | cost of MS in Europe (year 2005) by resource use components.~ ~
185 II, 5. 5. 3 | Code was drawn up in spring 2005 as follow up to the above
186 II, 5. 5. 3 | Zettl UK , Götze U, et al (2005): [MS registry in Germany—
187 II, 5. 5. 3 | results of the extension phase 2005/2006. Poster presentation
188 II, 5. 5. 3 | 138.~Global Health Atlas (2005). Available at: htt rg Accessed
189 II, 5. 5. 3 | Accessed June 14 2005.~Granieri E, Malagú S, Casetta
190 II, 5. 5. 3 | Riise T, Sotgiu MA, et al (2005): Increasing incidence of
191 II, 5. 5. 3 | von Campenhausen et al, 2005). It mainly affects voluntary
192 II, 5. 5. 3 | respectively (Nath et al, 2005; Orphanet, 2007; Vanacore,
193 II, 5. 5. 3 | Orphanet, 2007; Vanacore, 2005).~Although, the disease
194 II, 5. 5. 3 | Committee, 2002; Hely et al, 2005).~PD mainly affects older
195 II, 5. 5. 3 | Europe (Andlin-Sobocki et al, 2005).~
196 II, 5. 5. 3 | available (Andlin-Sobocki et al, 2005; Dowding et al, 2006; Lindgren
197 II, 5. 5. 3 | al, 2006; Lindgren et al, 2005; von Campenhausen et al,
198 II, 5. 5. 3 | von Campenhausen et al, 2005).~ ~ ~ ~
199 II, 5. 5. 3 | von Campenhausen et al, 2005).~ ~Table 5.5.3.6.2. Prevalence
200 II, 5. 5. 3 | al, 2003; Spottke et al, 2005). A generally accepted way
201 II, 5. 5. 3 | is about 1.8 (Hely et al, 2005; Hely et al, 1999). The
202 II, 5. 5. 3 | Andlin-Sobocki et al, 2005). The cost per case differed
203 II, 5. 5. 3 | al, 1999; Lindgren et al, 2005; McCrone et al, 2007; Spottke
204 II, 5. 5. 3 | al, 2007; Spottke et al, 2005). Direct cost only reflect
205 II, 5. 5. 3 | al, 1999; Spottke et al, 2005). Nevertheless, also a decrease
206 II, 5. 5. 3 | study (Andlin-Sobocki et al, 2005) also demonstrate that the
207 II, 5. 5. 3 | et al, 2002; Logroscino, 2005; Tanner, 2003; Tanner and
208 II, 5. 5. 3 | Europe (Andlin-Sobocki et al, 2005). Parkinson’s disease has
209 II, 5. 5. 3 | most populous nations: in 2005, the number of individuals
210 II, 5. 5. 3 | Wittchen HU, Olesen J (2005): Cost of disorders of the
211 II, 5. 5. 3 | the most populous nations, 2005 through 2030. Neurology
212 II, 5. 5. 3 | Reid WG, Trafficante R (2005): Sydney Multicenter Study
213 II, 5. 5. 3 | Spottke E, Siebert U, Dodel R (2005): Cost of Parkinson’s disease
214 II, 5. 5. 3 | Suppl 1:68-73.~Logroscino G (2005): The role of early life
215 II, 5. 5. 3 | Lees A, Rooney C, Burn D (2005): Population based mortality
216 II, 5. 5. 3 | Oertel WH, Ulm G, Dodel R (2005): Cost of illness and its
217 II, 5. 5. 3 | 6):549-554.~Vanacore N (2005): Epidemiological evidence
218 II, 5. 5. 3 | Siebert U, Berger K, Dodel R (2005): Prevalence and incidence
219 II, 5. 6. 2 | Bone and Joint Decade, Lund 2005 (European Commission (2004):
220 II, 5. 6. 2 | Current Osteoporosis Reports 2005; 3: 84-91 (Woolf and Pfleger,
221 II, 5. 6. 2 | 84-91 (Woolf and Pfleger, 2005)~ ~The content of this chapter
222 II, 5. 6. 3 | years (Hulsemann et al, 2005). These costs are strongly
223 II, 5. 6. 3 | over 50 (Kanis and Johnell, 2005).~ ~Most distal forearm
224 II, 5. 6. 6 | Schulenburg JM, Zeidler H, Ruof J (2005): Direct Costs Related to
225 II, 5. 6. 6 | Kanis JA and Johnell O (2005): Requirements for DXA for
226 II, 5. 6. 6 | 95~Woolf AD, Pfleger B (2005): Burden of osteoporosis
227 II, 5. 7. 1 | exhibit CKD (Coresh et al, 2005 ). Estimates in Asia and
228 II, 5. 7. 1 | and Australia (Chen et al, 2005; Chadban et al, 2003) indicate
229 II, 5. 7. 1 | completed (Viktorsdottir et al., 2005; Otero et al., 2005; de
230 II, 5. 7. 1 | al., 2005; Otero et al., 2005; de Zeeuw D et al., 2005;
231 II, 5. 7. 1 | 2005; de Zeeuw D et al., 2005; Hallan et al. 2006a; Hallan
232 II, 5. 7. 1 | chronic diseases in the 2005 WHO report (World Health
233 II, 5. 7. 1 | World Health Organization, 2005; Yach et al, 2004). However,
234 II, 5. 7. 1 | 2003; Gansevoort et al, 2005) may be useful for the screening
235 II, 5. 7. 1 | adults (Gorodetskaya et al, 2005; Kimmel and Patel, 2006)
236 II, 5. 7. 1 | U.S. Renal Data System, 2005).~ ~Definitions~ ~Whenever
237 II, 5. 7. 2 | RRT over the period 1992-2005 are incomplete. Seven EU-15
238 II, 5. 7. 3 | Esbjorner et al, 1997). In 2005 the incidence rate of RRT
239 II, 5. 7. 3 | difficulties (Winkelmayer et al, 2005). No data has been published
240 II, 5. 7. 3 | x years (Kurella et al, 2005). Similarly scarce are the
241 II, 5. 7. 3 | NHANES data (Coresh et al,2005).~ ~In Europe similar data
242 II, 5. 7. 3 | obesity and diabetes.~ ~In 2005 the incidence rates of RRT
243 II, 5. 7. 3 | rate of RRT for ESRD in 2005 steeply increased with age
244 II, 5. 7. 3 | rates in Canada (160 pmp in 2005) are similar to those in
245 II, 5. 7. 3 | in US whites (286 pmp in 2005) (U.S. Renal Data System,
246 II, 5. 7. 3 | Incidence of RRT over the 1992-2005 period per age group, gender
247 II, 5. 7. 3 | Incidence of RRT over the 1992-2005 period per country~ ~Table
248 II, 5. 7. 3 | Incidence of RRT over the 2000-2005 period per country.~ ~Trends
249 II, 5. 7. 3 | adolescents or adults.~In the 1992-2005 period the incidence rate
250 II, 5. 7. 3 | al, 2003; van Dijk et al, 2005) After 2002, the incidence
251 II, 5. 7. 3 | Heijden et al, 2004). In 2005 the prevalence of RRT in
252 II, 5. 7. 3 | Netherlands (De Zeeuw et al, 2005) and in Spain (Garcia-Lopez
253 II, 5. 7. 3 | Iceland) (Viktorsdottir et al, 2005) in females (Figure 5.7.
254 II, 5. 7. 3 | Iceland (Viktorsdottir et al, 2005), Norway (Hallan et al,
255 II, 5. 7. 3 | disease by age and sex.~ ~In 2005 the crude prevalence of
256 II, 5. 7. 3 | RRT over the period 1992-2005 by country.~ ~Table 5.7.
257 II, 5. 7. 3 | RRT over the period 2000-2005 by country.~ ~Table 5.7.
258 II, 5. 7. 3 | RRT over the period 1992-2005 by age group, gender and
259 II, 5. 7. 3 | Europe over the period 1992-2005 (Table 5.7.7) the overall
260 II, 5. 7. 3 | 2007; ERA-EDTA Registry, 2005). Also within Europe there
261 II, 5. 7. 3 | al, 2003; van Dijk et al, 2005) After 2002 the incidence
262 II, 5. 7. 5 | provided (Gansevoort et al, 2005) . Patients with neoplasia
263 II, 5. 7. 5 | dialysis patients. Since 2005, it has been mandatory for
264 II, 5. 7. 7 | S1-S85.~Annual data report 2005., Bethesda, MD: United States
265 II, 5. 7. 7 | Digestive and Kidney Diseases; 2005.~Ardissino G, Dacco V, Testa
266 II, 5. 7. 7 | Spruill M, Reynolds K, et al (2005) Prevalence of decreased
267 II, 5. 7. 7 | to 74 years. Kidney Int 2005;68(6):2839-45.~Chobanian
268 II, 5. 7. 7 | Eggers PW, Lacher DA, et al (2005): Chronic kidney disease
269 II, 5. 7. 7 | to 2000. J Am Soc Nephrol 2005 Jan;16(1):180-8.~de Zeeuw
270 II, 5. 7. 7 | Hillege HL, de Jong PE (2005): The kidney, a cardiovascular
271 II, 5. 7. 7 | therapy. Kidney Int Suppl 2005 Sep;(98):S25-S29.~Diez Roux
272 II, 5. 7. 7 | 702.~ERA-EDTA Registry (2005): 2005 Annual Report. Academic
273 II, 5. 7. 7 | ERA-EDTA Registry (2005): 2005 Annual Report. Academic
274 II, 5. 7. 7 | Bakker SJ, de Zeeuw, et al (2005): The validity of screening
275 II, 5. 7. 7 | population. Kidney Int Suppl 2005 Apr;(94):S28-S35.~Garcia-Lopez
276 II, 5. 7. 7 | Hsu CY, Bindman AB, et al (2005): Health-related quality
277 II, 5. 7. 7 | kidney disease. Kidney Int 2005 Dec;68(6):2801-8.~Hallan
278 II, 5. 7. 7 | Kurella M, Lo JC, Chertow GM (2005): Metabolic syndrome and
279 II, 5. 7. 7 | adults. J Am Soc Nephrol 2005 Jul;16(7):2134-40.~Levey
280 II, 5. 7. 7 | Garcia F, de Francisco AL (2005): Epidemiology of chronic
281 II, 5. 7. 7 | study. Kidney Int Suppl 2005 Dec;(99):S16-S19.~Pontoriero
282 II, 5. 8. 3 | study by Lindberg et al. (2005), in a symptomatic cohort
283 II, 5. 8. 3 | study by Johannessen et al (2005) reported cumulative incidence
284 II, 5. 8. 3 | 3% COPD) (Murtagh et al, 2005).~ ~The WHO’s Large Analysis
285 II, 5. 8. 3 | 2025 (Hoogendoorn et al, 2005). As regards the measurement
286 II, 5. 8. 3 | COPD (Hoogendoorn et al, 2005) in males and 3..9, 8.1,
287 II, 5. 8. 3 | health-care system (Sidney et al, 2005). These were diabetes, hypertension,
288 II, 5. 8. 3 | study by Soriano et al (2005), the UK General Practice
289 II, 5. 8. 4 | al, 2001; Sunyer et al, 2005).~ ~The exact prevalence
290 II, 5. 8. 7 | Lammers JW, Verheij TJ (2005): Prevalence of undetected
291 II, 5. 8. 7 | 65 years old. Fam Pract 2005; 22: 485-489.~ ~Goodridge
292 II, 5. 8. 7 | Omenaas E, Bakke P, Gulsvik A (2005): Incidence of GOLD-defined
293 II, 5. 8. 7 | population. Int J Tuberc Lung Dis 2005; 9: 926-932.~ ~Jorgensen
294 II, 5. 8. 7 | Larsson LG, Lundback B (2005): Ten-year cumulative incidence
295 II, 5. 8. 7 | symptomatic cohort. Chest 2005; 127: 1544-1552.~ ~Lindberg
296 II, 5. 8. 7 | Patterson C, MacMahon J (2005): Prevalence of obstructive
297 II, 5. 8. 7 | NICECOPD study. Eur J Epidemiol 2005; 20: 443-453.~Niederlander
298 II, 5. 8. 7 | Medical Care Program. Chest 2005; 128: 2068-2075.~ ~Soriano
299 II, 5. 8. 7 | Payvandi N, Hansell AL (2005): Patterns of comorbidities
300 II, 5. 8. 7 | asthma in primary care. Chest 2005; 128: 2099-2107.~ ~Soriano
301 II, 5. 8. 7 | Respiratory Health Survey (2005): Lung Function Decline,
302 II, 5. 9. 2 | collected at the end of 2005.~ ~In early 1990s two large
303 II, 5. 9. 3 | ISAYA) (Bugiani et al, 2005), the prevalence of allergic
304 II, 5. 9. 3 | decreased from 1995 until 2005 (-52%) (Tuberkulóza a respirační
305 II, 5. 9. 3 | Tuberkulóza a respirační nemoci 2005; htt ). All these data underline
306 II, 5. 9. 4 | Custovic, 2003; Simpson , 2005; Erwin, 2005). Exposure
307 II, 5. 9. 4 | Simpson , 2005; Erwin, 2005). Exposure to house dust
308 II, 5. 9. 4 | pet ownership (Fasce L, 2005), but may also be in part
309 II, 5. 9. 7 | 37, 788–79~ ~Bugiani M (2005): Allergic rhinitis and
310 II, 5. 9. 7 | adults in Italy. Allergy 2005, 60:165-170~ ~Burney PGJ (
311 II, 5. 9. 7 | Woodfolk JA, Platts-Mills TA (2005): Asthma and indoor air:
312 II, 5. 9. 7 | and dust-mite. Indoor Air. 2005;15 Suppl 10:33-9.~ ~European
313 II, 5. 9. 7 | Pistorio A, Rossi GA. (2005): “Early” cat ownership
314 II, 5. 9. 7 | Ann All Asthma Immunol 2005;94:561-565.~ ~Global Initiative
315 II, 5. 9. 7 | C, Svanec C, Kunzly N, (2005): Change in prevalence of
316 II, 5. 9. 7 | with age and cohort. JACI 2005;116:675-682).~ ~Keil T (
317 II, 5. 9. 7 | Curr Allergy Asthma Rep. 2005 May; 5(3):212-20.~ ~S P (
318 II, 5. 10. 3 | Source: Fasano and Catassi (2005)~ ~ ~ ~
319 II, 5. 10. 5 | implemented as of 25 November 2005. It is of renowned that
320 II, 5. 10. 5 | expressed as SO2 .~ ~Directive 2005/26/EC~- Lupin and products
321 II, 5. 10. 5 | substances. Commission Directive 2005/26/EC establishing a list
322 II, 5. 10. 5 | Commission on 21st March 2005, following the opinions
323 II, 5. 10. 7 | European Commission (2005): Commission Directive 2005/
324 II, 5. 10. 7 | 2005): Commission Directive 2005/26/EC of 21 March 2005 establishing
325 II, 5. 10. 7 | Directive 2005/26/EC of 21 March 2005 establishing a list of food
326 II, 5. 10. 7 | European Union L 75, 22.03.2005, pp. 33–34.~htt ~ ~European
327 II, 5. 10. 7 | R, Booth IW, McDonald A (2005): Consequences of perceived
328 II, 5. 11. 3 | C Lidén and K Norberg, 2005). In a study published in
329 II, 5. 11. 3 | different. In Italy, in 2005, the percentage of subjects
330 II, 5. 11. 3 | same level (T Hasan et al. 2005).~ ~ ~From an experimental
331 II, 5. 11. 3 | study, Contact Dermatitis, 2005;53:40–45.~CS Jensen, S Lisby,
332 II, 5. 11. 3 | Directive, Contact Dermatitis, 2005;52:29–35.~L Matt o, Prevalence
333 II, 5. 11. 3 | and Germany (Fouere et al, 2005). The disease afflicts men
334 II, 5. 11. 7 | Fouere S, Adjadj L, Pawin H (2005): How patients experience
335 II, 5. 11. 7 | Eur Acad Dermatol Venereol 2005;19(S3):2-6.~ ~Gudjonsson
336 II, 5. 11. 7 | 2007;25:535-546.~ ~Hay R (2005): Literature review. Onychomycosis.
337 II, 5. 11. 7 | Acad Dermatol Venereol. 2005;19 (S1):1-7.~ ~Herd RM,
338 II, 5. 12. 2 | National Cancer Institute, 2005).~Alcohol consumption data (
339 II, 5. 12. 3 | countries (de la Pena et al, 2005; Ioannou et al, 2003; Poynard
340 II, 5. 12. 5 | Margolis, 1990; Stroffolini, 2005). In the absence of a vaccine,
341 II, 5. 12. 5 | al, 2004; Shepard et al, 2005).~ ~ ~ ~Secondary prevention
342 II, 5. 12. 7 | National Cancer Institute (2005): Joinpoint Regression Program,
343 II, 5. 12. 7 | CW, Finelli L, Alter MJ (2005): Global epidemiology of
344 II, 5. 12. 7 | 558-567.~ ~Stroffolini T (2005): The changing pattern of
345 II, 5. 13 | the European Communities, 2005; WHO, 2000). A body mass
346 II, 5. 13 | Regional Office for Europe, 2005).~ ~Lifestyle factors, including
347 II, 5. 13 | the European Communities, 2005). In 2002, the total direct
348 II, 5. 13 | per year (Fry and Finley, 2005). The WHO Regional Office
349 II, 5. 14. 2 | factors (Petersen et al, 2005). Few countries in Western
350 II, 5. 14. 5 | burdens (Petersen et al, 2005). Increasingly European
351 II, 5. 14. 5 | Petersen and Yamamoto, 2005). An EU oral health strategy
352 II, 5. 14. 8 | D, Bratthal D, Ogawa H (2005): Oral health information
353 II, 5. 14. 8 | Bull World Health Organ. 2005; 83: 686-693.~Petersen PE,
354 II, 5. 14. 8 | Estupinan-Day S, N’Diaye C (2005): The global burden of oral
355 II, 5. 14. 8 | Bull World Health Organ. 2005; 83: 661-669.~Petersen PE,
356 II, 5. 14. 8 | Petersen PE, Yamamoto T (2005): Improving the oral health
357 II, 5. 14. 8 | Community Dent Oral Epidemiol 2005; 33: 81–92.~Selwitz RH,
358 II, 5. 15. 1 | health authorities (Eurordis, 2005).~ ~
359 II, 5. 15. 2 | unknown aetiology (Orphanet, 2005). The definition of what
360 II, 5. 15. 3 | 2006; Clarke, 2006; McCabe, 2005). Currently over 40 new
361 II, 5. 15. 4 | languages in June 2001. In 2005, Member States were asked
362 II, 5. 15. 4 | incentives as of the end of 2005.~ ~In 2000, a Committee
363 II, 5. 15. 6 | Medicinal Products, Revision 2005. Available at: htt , (accessed
364 II, 5. 15. 6 | accessed 12.05.2007)~Eurordis (2005): Rare diseases: understanding
365 II, 5. 15. 6 | Claxton K, Tsuchiya A (2005): Orphan drugs and the NHS:
366 II, 5. 15. 6 | should we value rarity? BMJ. 2005 Oct 29;331(7523):1016-9.~
367 II, 6. 1 | communicable diseases in 2005 in the 25 EU countries and
368 II, 6. 2 | official data for the year 2005 reported by the countries,
369 II, 6. 3. 1 | of general trends (1995–2005), EU incidence (2005), main
370 II, 6. 3. 1 | 1995–2005), EU incidence (2005), main age groups affected (
371 II, 6. 3. 1 | main age groups affected (2005), and major threats detected (
372 II, 6. 3. 1 | major threats detected (2005) for diseases reported on
373 II, 6. 3. 3 | with HIV/AIDS at the end of 2005 and that about 15 000 individuals
374 II, 6. 3. 3 | countries.~ ~Risk factors~ ~In 2005, 28 044 HIV diagnoses were
375 II, 6. 3. 3 | generally continued throughout 2005, i.e. a rise in diagnoses
376 II, 6. 3. 3 | With 171 cases reported in 2005, mother-to-child transmission
377 II, 6. 3. 3 | shows a stable trend). In 2005, 203 691 cases of Chlamydia
378 II, 6. 3. 3 | since then (figure 6.3). In 2005, a total of 27 537 cases
379 II, 6. 3. 3 | overall decreasing trend. In 2005, 12 945 syphilis cases were
380 II, 6. 3. 3 | 6 977 cases reported in 2005 by 26 countries, the highest
381 II, 6. 3. 3 | surveillance artefact. In 2005, more than 29 000 hepatitis
382 II, 6. 3. 4 | strain of the 2004–05 and 2005–06 winter seasons was mainly
383 II, 6. 3. 4 | pandemic was a main concern in 2005. Starting in late summer,
384 II, 6. 3. 4 | domestic poultry.~ ~Since 2005 there has been an extraordinary
385 II, 6. 3. 4 | substantially between 2001 and 2005, largely as a result of
386 II, 6. 3. 4 | Figure 6.A1.3 Combined MDR in 2005~ ~ ~ ~ ~Figure 6.A1.4 New
387 II, 6. 3. 4 | drug resistance low.~ ~ ~In 2005, the 25 EU countries plus
388 II, 6. 3. 4 | per 100 000 per year in 2005) and will effectively increase
389 II, 6. 3. 4 | important.~ ~In the EU in 2005, 22% of AIDS cases had TB
390 II, 6. 3. 4 | and 3.5%, respectively in 2005.~ ~Control tools and policies~ ~
391 II, 6. 3. 4 | per 100 000 per year. In 2005, a total of 4 189 human
392 II, 6. 3. 4 | per 100 000 per year. In 2005, 746 cases of travel-associated
393 II, 6. 3. 4 | Legionnaires’ disease with onset in 2005 were reported to the EWGLINET
394 II, 6. 3. 4 | also appeared in Europe in 2005, the EU was largely spared
395 II, 6. 3. 4 | reported in the world in 2005.~Today, the most likely
396 II, 6. 3. 5 | the UK (increasing). In 2005, a total of 19 665 invasive
397 II, 6. 3. 5 | introduction of the vaccine. In 2005, a total of 5 494 cases
398 II, 6. 3. 5 | Ireland and the UK. In 2005, 1 145 cases were reported
399 II, 6. 3. 5 | groups (0–14 years).~ ~In 2005, a total of 13 207 cases
400 II, 6. 3. 5 | observed sporadically. In 2005, only Latvia reported cases (
401 II, 6. 3. 5 | in 2002 (two cases). In 2005, altogether 137 cases were
402 II, 6. 3. 5 | per year since 2000.~ ~In 2005, a total of 1 291 cases
403 II, 6. 3. 5 | vaccine.~ ~Between 1996 and 2005, there was a generally decreasing
404 II, 6. 3. 5 | Spain in 1996 and 2000.~ ~In 2005, a total of 52 918 cases
405 II, 6. 3. 5 | 1996 and Spain in 1996.~In 2005, a total of 1 498 cases
406 II, 6. 3. 6 | between 1995 - 2004~ ~In 2005, more than 200 000 cases
407 II, 6. 3. 6 | parts of the world.~ ~In 2005, a total of 181 876 human
408 II, 6. 3. 6 | and 2004 (6 440 cases). In 2005, a total of 1 364 human
409 II, 6. 3. 6 | slight peak in 2001. In 2005, a total of 7 425 human
410 II, 6. 3. 6 | appears to be 0–4 year one. In 2005, a total of 5 218 cases
411 II, 6. 3. 6 | outbreaks were monitored in 2005, with beef, lettuce and
412 II, 6. 3. 6 | seen in 1998 and 2002. In 2005, 23 countries notified a
413 II, 6. 3. 6 | reported 1 491 cases in 2005. Denmark (0.85 per 100 000),
414 II, 6. 3. 6 | over 65 years of age. In 2005, 96 listeriosis cases were
415 II, 6. 3. 6 | reported 1 429 cases in 2005, with an overall incidence
416 II, 6. 3. 6 | over the 10-year period. In 2005, a total of 152 cases were
417 II, 6. 3. 6 | per 100 000 per year). In 2005, 34 cases were reported
418 II, 6. 3. 6 | remained stable since then. In 2005, 6 695 cases were reported
419 II, 6. 3. 6 | decreasing trend since then. In 2005, 1 519 toxoplasmosis cases
420 II, 6. 3. 6 | over the last 10 years. In 2005, some 15 103 cases were
421 II, 6. 3. 6 | trend data are scanty. In 2005, almost 8 000 cases were
422 II, 6. 3. 6 | decreasing since 1996. In 2005, altogether 337 cases were
423 II, 6. 3. 6 | been relatively stable. In 2005, 153 cases were reported
424 II, 6. 3. 6 | declined steadily until 2004~In 2005, a total of 21 cases were
425 II, 6. 3. 7 | although more in Sweden. In 2005, 508 cases were reported
426 II, 6. 3. 7 | every third year. The year 2005 saw one of these peaks,
427 II, 6. 3. 7 | 5 cases per 100 000. In 2005, 958 cases were reported
428 II, 6. 3. 7 | overseas departments. In 2005, 900 cases were reported
429 II, 6. 3. 7 | followed by Greece (14%). In 2005, 21 countries reported just
430 II, 6. 3. 7 | EU (total 21 cases). In 2005, five cases of rabies were
431 II, 6. 3. 7 | Malaria trends in Europe~ ~In 2005, 4 306 malaria cases were
432 II, 6. 3. 7 | identified as a threat in 2005, are discussed here below.
433 II, 6. 3. 7 | of DHF were reported in 2005.~ ~Lassa fever is endemic
434 II, 6. 3. 7 | No cases were reported in 2005.~ ~Crimean-Congo haemorrhagic
435 II, 6. 3. 7 | No cases were reported in 2005.~ ~Ebola and Marburg haemorrhagic
436 II, 6. 3. 7 | the UK in 1998, 2001 and 2005, and two cases from Ireland
437 II, 6. 4. 3 | Commission organised in 2005 two scenario exercises (
438 II, 6. 4. 4 | inaugurated in Stockholm in May 2005.~ ~In accordance with its
439 II, 7. 1 | and safety promotion:~ ~In 2005 the WHO has passed a Regional
440 II, 7. 3 | Statistics summary 2003 – 2005” (see KfV, 2007)1. See also
441 II, 7. 3 | mostly for the period 2003-2005.~ ~
442 II, 7. 3. 2 | the EU. Based on the 2003-2005 figures for all ages, Lithuania
443 II, 7. 3. 3 | to injuries, EU27, 2003-2005~ ~On average about 1 500
444 II, 7. 4. 2 | a factor of two between 2005 and 2050, a significant
445 II, 7. 4. 3 | provided by Avenso & Beckmann, 2005.~ ~In the field of road
446 II, 7. 4. 4 | time of injury, EU27, 2003-2005~ ~The “sport injuries” priority
447 II, 7. 4. 4 | injury by age group, 2003-2005~ ~Physical exercise contributes
448 II, 7. 4. 6 | Organization, 2005c).~ ~In October 2005, the European Commission
449 II, 7. 7 | 3 year average of 2003-2005. [https://webgate.ec.europa.
450 II, 7. 7 | European Injury Database (2005): Home and leisure accidents
451 II, 7. 7 | Statistics Summary 2003-2005. Vienna: Austrian Road Safety
452 II, 7. 7 | RC55/R9 of September 15, 2005. Copenhagen, WHO Regional
453 II, 8. 1. 5 | of the Action Plan (2004-2005) addressed the establishment
454 II, 8. 1. 5 | priorities for action during 2004-2005. The second phase of the
455 II, 8. 1. 5(6) | COM(2005)604 http df~
456 II, 8. 2. 1 | disparities (Scheepers et al., 2005). The European Union Health
457 II, 8. 2. 1 | conducted over two decades (1986-2005), with the majority (60%)
458 II, 8. 2. 1 | example (Ouellette-Kuntz 2005). Among people with intellectual
459 II, 8. 2. 1 | disabilities (Scheepers et al 2005) are among the factors likely
460 II, 8. 2. 1 | accommodation in England, Emerson (2005) found significant deviations
461 II, 8. 2. 1 | disabled people (Lennox, 2005). Pending approval, the
462 II, 8. 2. 1 | disabilities (Scheepers, Kerr et al 2005). At European Community
463 II, 8. 2. 1 | expectancy increases (Walsh 2005). Reflecting social policies
464 II, 8. 2. 1 | 667–677.~Emerson, E. (2005) Underweight, obesity and
465 II, 8. 2. 1 | and Rutkowski-Kmitta, V. (2005). Disability Statistics
466 II, 8. 2. 1 | Developmental Disability (2005) Melbourne, Australia: Therapeutic
467 II, 8. 2. 1 | 90~Ouellette-Kuntz, H., (2005). Understanding Health Disparities
468 II, 8. 2. 1 | Meaney J & Wehmeyer M (2005). Reducing health disparity
469 II, 8. 2. 1 | Jørgensen, F., & O’Farrell, L., (2005). Brief Research Report
470 II, 8. 2. 2 | Ireland (Donnelly et al, 2005) and Italy (Nucci et al,
471 II, 8. 2. 2 | and Italy (Nucci et al, 2005). The results indicate a
472 II, 8. 2. 2 | Ireland (Donnelly et al, 2005) and Italy (Nucci et al,
473 II, 8. 2. 2 | and Italy (Nucci et al, 2005). The results indicate a
474 II, 8. 2. 2 | Stewart NM and Hollinger M. (2005): Prevalence and outcomes
475 II, 8. 2. 2 | Corsi A and Cerulli L. (2005): Incidence of visual loss
476 II, 9 | Clearly-Goldman et al, 2005; Luke and Brown, 2007a;
477 II, 9 | pregnancies (Ananth et al, 2005; Garite et al, 2004). Figures
478 II, 9 | Percentage of mothers under 20 in 2005 or most recent year~ ~Fi ~ ~
479 II, 9 | with ART (Hansen et al, 2005). Particularly stringent
480 II, 9 | living in poverty (UNICEF, 2005). Data on maternal education
481 II, 9 | mineral deficiency (Volkert, 2005). Obtaining adequate nutrition
482 II, 9 | in the elderly (Volkert, 2005). Healthy food and eating
483 II, 9 | active elderly (Volkert, 2005). The level of physical activity
484 II, 9. 1. 1 | and infant mortality for 2005 or most recent available
485 II, 9. 1. 1 | selected EUGLOREH countries in 2005 or most recent year~ ~Congenital
486 II, 9. 1. 1(1) | based on one year data (2005) and 25 deaths only.~
487 II, 9. 1. 1 | Demissie K, Vintzileos AM (2005): Trends in twin preterm
488 II, 9. 1. 1 | mortality. Am J Obstet Gynecol 2005;193(3 Pt 2):1076-82.~ ~Alexander
489 II, 9. 1. 1 | DA, Comstock CH, et al (2005): Impact of maternal age
490 II, 9. 1. 1 | outcome. Obstet Gynecol 2005;105(5 Pt 1):983-90.~Cnattingius
491 II, 9. 1. 2 | Clearly-Goldman et al, 2005; Luke and Brown, 2007a;
492 II, 9. 1. 2 | pregnancies (Ananth et al, 2005; Garite et al, 2004). Figures
493 II, 9. 1. 2 | Percentage of mothers under 20 in 2005 or most recent year~ ~Figure
494 II, 9. 1. 2 | with ART (Hansen et al, 2005). Particularly stringent
495 II, 9. 1. 2 | Abramsky et al, 2007; EUROCAT, 2005) and is the major primary
496 II, 9. 1. 2 | across Europe (EUROCAT, 2005). Screening policies vary
497 II, 9. 1. 2 | European countries (EUROCAT, 2005), and even countries with
498 II, 9. 1. 2 | implementation (EUROCAT, 2005).~ ~An increasing proportion
499 II, 9. 1. 2 | et al, 2004; Garne et al, 2005). Such variation may result
500 II, 9. 1. 2 | insufficient and short-term. In 2005, approximately 4 million
|
|
| |
